argenx focuses on innovating immunology solutions to reach patients.

argenx

IPhone / Mobile Compatible

Domain Not Resolving

Microsoft Exchange Online

Office 365 Mail

Microsoft Azure DNS

ASP.NET

Common Name Invalid

Sectigo SSL

General Counsel

Dirk Beeusaert

Chief Operating Officer

R. Keith Woods

Chief Medical Officer

Wim Parys

Global Head of QA

Andria Wilk

Operations

Arpad Simon

Vice President US Sales, Neurology Franchise

Brad Mathis

VP - Sales & Market Development

Dan Dugan

Head of Regional Access at Argenx

Patrick Mumme

General Manager, US

Rebecca McLeod

Keith Woods

Christophe Blanchetot

Director Discovery

Tom Hughes

HEOR Launch Consultant

Carine Rivet-Thions

Associate Director Regulatory Affairs Labeling

Hans De Haard

Peter Verheesen

Research Fellow

Tim Van Hauwermeiren

Founder and CEO

Karen Massey

Halozyme Therapeutics develops extracellular matrix targeting products for the insulin, cancer, dermatology and drug delivery markets.

Biotechnology Public Companies With More Than 100 Employees

New England Biotechnology Companies

Massachusetts Companies With Less Than $500M in Revenue (Top 10K)

East Coast Companies that Exited (Top 10K)

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.

Post-IPO Equity - argenx

Grant - argenx

OrbiMed

Seventure Partners

Series B - argenx

Series A - argenx

Forbion Capital Partners

Boston

Massachusetts

United States

North America

argenx to Present at Upcoming Investor Conferences

OncoVerity Raises Extended Series A

argenx to Participate at Upcoming Investor Conferences

The Latest Analyst Ratings For argenx

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®

Argenx tops BEL 20 index, broker points to positive Vyvgart momentum

Here’s Why argenx SE (ARGX) Rose 9% in Q2

An investigational antibody fragment targeting the neonatal Fc receptor (FcRn) for treating severe autoimmune diseases with pathogenic IgG autoantibodies.

A humanized sweeping antibody designed to inhibit C2 and downstream complement activation for severe IgM-driven autoimmune diseases.

A human IgG1 anti-C2 sweeping antibody with enhanced FcRn binding to prevent degradation and improve C2 clearance from the bloodstream.

South Korea

Asia

Belgium

Europe

Spain

United Kingdom

HTML5

Google Tag Manager

jQuery

.NET 4.5

Vimeo

Microsoft Outlook

Office 365

Apache Server

Google Analytics

Google Fonts

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

argenx SE

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 26, 2024 1:57 PM	4a1dc988
news daily refresh	general	Dec 4, 2024 2:16 PM	a8db654c
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 26, 2024 1:57 PM	f3dda6ec
crunchbase trigger	general	Dec 4, 2024 8:54 AM	eecd6e74
crunchbase profile	general	Dec 4, 2024 12:45 PM	5bb60841
li profile	general
translate crunchbase fundingrounds	general	Dec 4, 2024 1:39 PM	b3652dee
peers	general	Sep 26, 2024 1:57 PM	7addbaab
news basic	general	Dec 4, 2024 2:13 PM	30e63bd0
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ARGENX

argenx

Last Close

582.60

25/11 09:24

Market Cap

25.12B

Beta: -

Volume Today

4.76K

Avg: -